Blood Pressure Guidelines Have Changed: What the 2025 Update Means for Nigerians

Blood pressure guidelines have evolved significantly over the past decade, changing not only how elevated readings are classified but also how clinicians assess cardiovascular risk and decide when treatment should begin.

The latest 2025 American College of Cardiology/American Heart Association (ACC/AHA) guideline replaces the 2017 guideline and introduces several important updates to the prevention, detection and management of high blood pressure in adults. [1]

For Nigerians, the update is relevant because hypertension remains a major public-health challenge. WHO estimates that 36.1% of Nigerian adults aged 30–79 years had hypertension in 2019. Of the estimated 19.1 million adults living with the condition, only 47% had been diagnosed, 29% were receiving treatment and 11% had their blood pressure controlled. [2]

First, What Changed in 2017?

The 2017 ACC/AHA guideline made a major change to blood-pressure classification.

It removed the term “prehypertension” and introduced “elevated blood pressure” for systolic blood pressure of 120–129 mmHg with diastolic blood pressure below 80 mmHg.

It also classified systolic blood pressure of 130–139 mmHg or diastolic blood pressure of 80–89 mmHg as Stage 1 hypertension. [3]

These changes were intended to identify cardiovascular risk earlier and encourage lifestyle interventions before blood pressure progressed further.

Importantly, this is not a new change in 2025. The 2025 guideline retains the same basic categories.

What Is New in the 2025 Guideline?

1. Cardiovascular risk now has a greater role in treatment decisions

One of the major changes is the use of the PREVENT risk equations to estimate a person's risk of developing cardiovascular disease.

For some adults with blood pressure of 130/80 mmHg or higher, the decision to start medication now depends not only on the blood-pressure reading but also on cardiovascular risk and conditions such as established cardiovascular disease, previous stroke, diabetes or chronic kidney disease. [1]

This means that two people with the same blood-pressure reading may not necessarily receive identical treatment recommendations.

2. The overall treatment goal is below 130/80 mmHg

The 2025 guideline recommends a general treatment goal of less than 130/80 mmHg for adults, while recognising that individual circumstances may require different considerations. [1]

The emphasis is therefore not simply on diagnosing hypertension, but on achieving sustained blood-pressure control.

3. More emphasis on home blood-pressure monitoring

The updated guideline gives greater importance to home blood-pressure monitoring as part of hypertension management.

Home measurements can provide additional information outside the clinical environment and help healthcare professionals assess whether blood pressure is consistently controlled. [1]

The guideline also cautions against relying on cuffless devices, including smartwatches, for accurate blood-pressure measurement until their precision and reliability are sufficiently established. [1]

4. Earlier medication treatment for some patients

Medication is recommended alongside lifestyle interventions for adults with average blood pressure of 140/90 mmHg or higher.

For people with average blood pressure of 130/80 mmHg or higher, medication may also be recommended when they have cardiovascular disease, previous stroke, diabetes, chronic kidney disease or a sufficiently high predicted cardiovascular risk.

For lower-risk adults, the guideline recommends an initial period of lifestyle modification before medication is considered if blood pressure remains at or above 130/80 mmHg. [1]

5. Two medicines may be started together in Stage 2 hypertension

For adults with Stage 2 hypertension, the guideline prefers starting treatment with two first-line antihypertensive medicines from different classes, preferably as a single-pill combination.

The aim is to improve adherence, simplify treatment and help patients reach blood-pressure targets more efficiently. [1]

This is particularly relevant to pharmacists because medication complexity and adherence are important considerations in long-term hypertension management.

6. Team-based care is emphasised

The updated guideline places greater emphasis on multidisciplinary care.

Pharmacists, nurses, dietitians, community health workers and other healthcare professionals can contribute alongside physicians to screening, treatment, medication management, education and follow-up. [1]

For community pharmacy practice, this reinforces the potential role of pharmacists in identifying elevated readings, supporting adherence, providing medicine-related counselling and referring patients who require further assessment.

What About a Reading of 180/120 mmHg?

Very high blood pressure requires prompt attention.

The 2025 guideline defines severe hypertension in non-pregnant adults as blood pressure above 180/120 mmHg without evidence of acute target-organ damage and recommends timely evaluation and treatment. [1]

However, very high blood pressure accompanied by symptoms such as chest pain, severe difficulty breathing, weakness, confusion, difficulty speaking or significant visual changes may indicate an acute medical emergency requiring urgent care.

People should not independently take additional doses of antihypertensive medicines in response to a very high reading unless instructed by a healthcare professional.

What Does This Mean for Nigerians?

The guideline provides a more individualised approach to hypertension care, but its implementation must be considered alongside Nigeria's own healthcare realities.

With substantial gaps in hypertension diagnosis, treatment and control, improving access to accurate blood-pressure measurement, affordable medicines, follow-up and patient education remains critical. [2]

For Nigerians, the practical message is straightforward: know your blood pressure, measure it properly and do not ignore persistently elevated readings.

A single high reading does not necessarily establish a diagnosis. Blood pressure should be assessed using appropriate measurement techniques and, where necessary, repeated measurements or home monitoring under professional guidance.

The Pharmacist's Role

Pharmacists are well positioned to contribute to hypertension control because of their accessibility and expertise in medicines.

Their role can include blood-pressure screening where appropriate, patient education, medication counselling, adherence support, identification of medicine-related problems and referral for further clinical assessment.

For patients already receiving treatment, pharmacists can also help address barriers to adherence and reinforce the importance of continued treatment even when the patient feels well.

The 2025 guideline's emphasis on multidisciplinary care provides further support for integrating pharmacists into coordinated hypertension management. [1]

The Bottom Line

The 2025 ACC/AHA guideline does not introduce a new blood-pressure classification system. The major classification change — including replacing “prehypertension” with “elevated blood pressure” — occurred in 2017.

What is new in the 2025 update is the greater emphasis on individual cardiovascular risk, a treatment goal below 130/80 mmHg, home blood-pressure monitoring, earlier treatment for selected patients, single-pill combination therapy and multidisciplinary care. [1]

For Nigeria, where hypertension remains common and control rates remain low, translating these recommendations into accessible screening, appropriate treatment, medication support and sustained follow-up will be essential.

For pharmacists, the update reinforces an increasingly important role in helping patients understand their blood pressure, use medicines appropriately and remain engaged in long-term cardiovascular care.

References

1. Jones DW, Ferdinand KC, Taler SJ, et al. 2025. Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;152:e114–e218. doi:10.1161/CIR.0000000000001356. Full guideline

2. World Health Organization. Hypertension Nigeria 2023 Country Profile. Geneva: WHO; 2023. WHO Nigeria hypertension profile

3. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018;71(6):e13–e115. doi:10.1161/HYP.0000000000000065. 2017 ACC/AHA guideline

4. World Health Organization. Guideline for the Pharmacological Treatment of Hypertension in Adults. Geneva: WHO; 2021. WHO hypertension guideline